The Latest Breaking News from JNJ

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

Amid rising healthcare demand globally, advancements in precision medicine, and the booming e-pharmacy market, the pharmaceutical industry is expected to witness significant long-term growth. Hence, fundamentally sound pharma stocks Dr. Reddy’s Laboratories (RDY), Ipsen (IPSEY), and Johnson & Johnson (JNJ), which boast low beta values and attractive valuation metrics, might…

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

Johnson & Johnson beat fourth-quarter expectations Tuesday, helped by strength from its medtech segment. But JNJ stock toppled.

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

High yields aren't the only reason to buy shares of dividend-paying stocks. For investors seeking quality dividend stocks for passive income, here's a look at two companies with long track records of raising shareholder payouts.

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….